Get the Stockscreener App
20.31
2.17%
-0.45
After Hours:
20.31
Oruka Therapeutics Inc stock is traded at $20.31, with a volume of 2.38M.
It is down -2.17% in the last 24 hours and down -8.51% over the past month.
Oruka Therapeutics Inc is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. It is to offer patients suffering from chronic skin diseases like plaque psoriasis.
See More
Previous Close:
$20.76
Open:
$20.31
24h Volume:
2.38M
Relative Volume:
11.68
Market Cap:
$710.82M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-7.43%
1M Performance:
-8.51%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$19.84
$21.58
1-Week Range:
$19.84
$23.57
52-Week Range:
$18.20
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
20.31 | 710.82M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-11-24 | Initiated | Stifel | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | Leerink Partners | Outperform |
| Sep-16-24 | Initiated | TD Cowen | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
Franklin Resources Inc. Takes $17.66 Million Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Receives "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright bullish on Oruka stock after early clinical success for ORKA-001 - Investing.com UK
Oruka Therapeutics doses first participants in Phase 1 trial of ORKA-001 - Yahoo Finance
Oruka Therapeutics enters exclusive licensing deal with Paragon - Investing.com
Oruka Therapeutics (NASDAQ:ORKA) Stock Price Down 4.7%What's Next? - MarketBeat
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody - The Manila Times
Oruka Therapeutics Announces First Participants Dosed in - GlobeNewswire
Oruka Therapeutics Launches Phase 1 Trial of Revolutionary Long-Acting Psoriasis Treatment ORKA-001 - StockTitan
Wellington Management Group LLP Acquires New Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Wellington Management Group LLP Takes $2.01 Million Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI) - The Manila Times
Oruka Therapeutics to Join Prestigious Nasdaq Biotechnology Index in Major Milestone - StockTitan
Oruka Therapeutics (NASDAQ:ORKA) Sees Large Volume IncreaseShould You Buy? - MarketBeat
The Manufacturers Life Insurance Company Invests $1.04 Million in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15% - Yahoo Finance
Frazier Life Sciences Management L.P. Purchases New Stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Janus Henderson Group PLC Acquires Shares of 236,116 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Point72 Asset Management L.P. Acquires Shares of 482,330 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
RTW Investments LP Takes $45.36 Million Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Redmile Group LLC Acquires Shares of 411,728 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Fmr LLC Buys Shares of 4,682,300 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Oruka Therapeutics: Strong Q3 and Strategic Advances - TipRanks
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Buy” by Brokerages - Defense World
Braidwell LP Acquires New Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Trading Up 7.4%Here's Why - MarketBeat
Great Point Partners LLC Takes $12.61 Million Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - MarketBeat
HC Wainwright Analysts Decrease Earnings Estimates for ORKA - MarketBeat
Oruka stock stays Buy-rated as H.C. Wainwright emphasizes annual dosing potential for ORKA-001 - Investing.com UK
ARCA BIOPHARMA, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Oruka Therapeutics (NASDAQ:ORKA) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Fairmount Funds Management LLC's Strategic Acquisition in Oruka Therapeutics Inc - GuruFocus.com
Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference - The Manila Times
Oruka Therapeutics to Present at Piper Sandler Healthcare Conference | Psoriasis Drug Developer | ORKA Stock News - StockTitan
Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference - GlobeNewswire
Oruka Therapeutics gains approval for preferred stock conversion - Investing.com
Oruka Therapeutics adjusts financials post-merger By Investing.com - Investing.com Canada
Oruka Therapeutics adjusts financials post-merger - Investing.com
JANUS HENDERSON GROUP PLC Acquires New Stake in Oruka Therapeuti - GuruFocus.com
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Oruka Therapeutics Raises $475M, Accelerates Clinical Timeline for Key Drug Programs | ORKA Stock News - StockTitan
Oruka Therapeutics to Present at Multiple November Investor Conferences - StockTitan
Oruka stock draws buy rating at Stifel (NASDAQ:ORKA) - Seeking Alpha
Oruka Therapeutics shares gain buy rating as H.C. Wainwright sees strong future in psoriasis treatment - Investing.com Canada
Oruka Therapeutics Adjusts Executive Severance Agreements - TipRanks
Anti-IL-23 antibody demonstrates potential for long-term dosing - BioWorld Online
Oruka Therapeutics (NASDAQ:ORKA) Stock Quotes, Forecast and News Summary - Benzinga
Oruka shares rise as TD Cowen maintains buy on drug potential - Investing.com Canada
Oruka Therapeutics reveals promising preclinical data for psoriasis treatment - Investing.com
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of ... - The Bakersfield Californian
Oruka Therapeutics Announces Preclinical Data for ORKA-001 - GlobeNewswire
Oruka Therapeutics Inc Stock (ORKA) Financials Data
There is no financial data for Oruka Therapeutics Inc (ORKA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Oruka Therapeutics Inc Stock (ORKA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 24 '24 |
Buy |
3.20 |
189,856 |
606,873 |
2,081,168 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 25 '24 |
Buy |
3.05 |
30,227 |
92,292 |
2,111,395 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 03 '24 |
Buy |
3.55 |
166,042 |
589,565 |
1,648,577 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 11 '24 |
Buy |
3.45 |
94,537 |
326,304 |
1,891,312 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 10 '24 |
Buy |
3.46 |
55,463 |
192,130 |
1,796,775 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 08 '24 |
Buy |
3.46 |
47,492 |
164,190 |
1,724,395 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 05 '24 |
Buy |
3.43 |
28,326 |
97,065 |
1,676,903 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Jul 09 '24 |
Buy |
3.43 |
16,917 |
58,091 |
1,741,312 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):